



AVICANNA™

Innovation in
R&D and cultivation in the
cannabis industry

Avicanna.com

Avicanna™

Corporate highlights



- **Multi-national & strategically positioned**

In North America and Latin America

- **Cultivation and R&D focused on 4 main product categories**

Cannabinoid-based pharmaceuticals, phyto-therapeutics, derma-cosmetics, and cannabis extracts/purified cannabinoids

- **Advanced cannabinoid research**

Lead by Dr. Christine Allen, Full Professor & interim Dean of the Leslie Dan Faculty of Pharmacy at The University of Toronto (“U of T”)

- **Headquartered in Johnson & Johnson Innovation’s JLABS @ Toronto**

Located in the Medical and Related Sciences (“MaRS”) Centre in Toronto, Canada

- **Clinical partnerships with world-renowned medical**

Institutions including The University of Toronto (“U of T”), University Health Network (“UHN”), The Hospital for Sick Children (“SickKids”), The University of West Indies (“UWI”)

- **Two fully operational cultivation projects in Colombia**

Low cost, sustainable and organic with GACP practices

- **Phase 1 - 410,000 sq. ft. combined canopy with capacity**

For estimated 24 tonnes of flower/year*

- **Health Canada certified GMP manufacturing partnership****



* Combined and estimated figures for both completed cultivation projects, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S..

** <https://www.alteafarma.com.co/home/>

About Avicanna™



Strategically positioned to be a front runner in the development, manufacturing and commercialization of plant-derived cannabinoid-based products.



R&D

Headquartered in **JLABS @ Toronto**, in the **MaRS Centre**, the world's largest urban innovation hub, where Avicanna's scientists conduct research with world-class academic and clinical institutions including the University of Toronto.



CULTIVATION

Low cost, industrial scale cultivation and extraction infrastructure through Avicanna's two subsidiaries in Santa Marta, Colombia, focused on **organic and environmentally sustainable practices**.



MANUFACTURING

GMP manufacturing (Health Canada)* and a growing network of distributors around the world of our 4 key product categories, plant-derived cannabinoid
(i) pharmaceuticals;
(ii) phyto-therapeutics;
(iii) derma-cosmetics; and,
(iv) cannabis extracts and purified cannabinoids.

University of Toronto
Faculty of Pharmacy

* <https://www.alteafarma.com.co/home/>

Research and Development (R&D)



A dedication to robust scientific development and evidenced-based clinical approach



Collaboration of scientists

Operating out of Toronto, Bogota and Santa Marta, Colombia



Clinical development programs

Ongoing clinical development programs to demonstrate product safety and efficacy with world-class clinical partnerships

- *SickKids Hospital, Toronto*
- *University Health Network, Toronto*
- *University of West Indies, Jamaica*
- *Caiced, Colombia*



University of Toronto

Exclusive research and collaboration agreement with Dr. Christine Allen's Research Group (CARG) in the Leslie Dan Faculty of Pharmacy. Services include formulation optimization, *in vitro* and *in vivo* analysis



Finalized product offerings

Fully developed and optimized product lines including Avicanna's proprietary derma-cosmetics and phyto-therapeutics.



Cultivation projects in Santa Marta, Colombia



Controlling interest in two companies in Colombia focused on commercial cannabis cultivation, **Sativa Nativa** and **Santa Marta Golden Hemp**



60% interest 16 hectares
[180,000 sq ft current capacity, 290,000 sq ft completed phase 1 project*]



70% interest 2.8 hectares
[70,000 sq ft current capacity, 120,000 sq ft completed phase 1 project*]



Optimal microclimate of Santa Marta and the foothills of the **Sierra Nevada Mountains**

Combined **2,000 kg/month** capacity*



High quality and **low cost** mass production of extracts

*We require approximately \$555,000 in total and approximately 2 months to complete phase 1 project for both subsidiaries

Environmentally Sustainable Cannabis Cultivation in Santa Marta Colombia



1

Sun-grown and **environmentally sustainable** practices



2

Competitive **cost advantages** including low cost labour, land and energy



3

Cultivated under **good agricultural** and **collection practices** (GACP)



4

Avicanna's proprietary extraction and purification processes



5

Licenses to cultivate CBD & THC dominant strains for processing and sales in the domestic market and exports

2 Fully Licensed and Operating Cultivation Subsidiaries



Santa Marta, Colombia

Santa Marta Golden Hemp ("SMGH") and Sativa Nativa ("SN") capacity

Current	SMGH	SN	Total
Current Cultivation Footprint	180,000 sq ft	70,000 sq ft	250,000 sq ft
Current Annual Capacity	12,000 kg	3,000 kg	15,000 kg
Phase 1 (Q2 2019)	SMGH*	SN*	Total
Projected Cultivation Footprint	290,000 sq ft	120,000 sq ft	410,000 sq ft
Projected Annual Capacity**	16,800 kg	7,200 kg	24,000 kg

*We require approximately \$555,000 in total and approximately 2 months to complete phase 1 project for both subsidiaries

**Registration of genetics must be completed before being approved for commercial production

Extracts and API's



Avicanna's extracts and pharmaceutical grade cannabinoids as active pharmaceutical ingredients (API) provided through its two subsidiaries in Santa Marta, Colombia

Avicanna's analytical laboratory and extraction laboratory in SMGH with capabilities to extract and isolate cannabinoids



GMP - Manufacturing partnership

Altea Farma*



altes
FARMA



Global GMP Certifications

- INVIMA (Colombia)
- HEALTH CANADA
- ANVISA (Brazil)
- DIGMID (Perú)
- EU



GMP Manufacturing of

- Pharmaceutical products
- Phyto-therapeutics products
- Dietary supplement products
- Cosmetic products



Dosage Forms

- Gels, creams, drops, lotions
- Tablets, capsules, pellets, chewable tablets

Clients:

Pfizer, Novartis, Merck,
GSK, Roche and Myland

*<https://www.alteafarma.com.co/home/>



PURELY
YOU

WWW.PURAEARTH.WORLD



Pura Earth™

CBD Derma-Cosmetics



PURA
EARTH™

Derma-cosmetic formulations to maintain and improve the health and beauty of the skin.

BEAUTY TREATMENTS

- Anti-aging Treatment
- Under Eye Treatment
- Regenerating Facial Serum
- Dark Spot Treatment



MOISTURIZE & PROTECTION



- Skin Protecting Face Lotion (AM)
- Skin Protecting Face Lotion (PM)
- Skin Protecting Body Lotion

SPECIALIZED CARE



- Clear Skin Treatment
- Intensive Conditioning Treatment



The product mock-ups that appear on this page are not indicative of final products that may be marketed and sold.



PURA
ELEMENTS™

**Elevating Nature
Through Science**

To continue to advance the world of
cannabinoid-based therapies

Pura Elements™

CBD-THC Phyto-therapeutics



Plant-derived cannabinoid-based therapies in a range of CBD and/or THC ratios, doses and forms of delivery.



Rapid or sustained release profiles

Natural **whole plant** extracts

Localized, deep penetrating or **transdermal** topical applications

RANGE OF INNOVATIVE DELIVERY SYSTEMS



The product mock-ups that appear on this page are not indicative of final products that may be marketed and sold.

Pharmaceuticals

Pipeline of indication specific products



Pharmaceutical product pipeline following the traditional drug discovery and development process for eventual submission to the applicable government agencies, such as Health Canada or the FDA.

Focus on 6 therapeutic areas and utilizing only isolated Extracts, our intention is to use the isolated Extracts produced by our subsidiaries in Colombia in the pharmaceutical products we will offer.

*All projects are in pre-clinical phases. Note that the regulatory process to bring these products to market is lengthy and complicated and Avicanna cannot currently comment as to when such products will come to market.



Dermatology



Pain



Neurology



Oncology



Gastrointestinal



Psychiatry

Current Pipeline in Various Stages of Pre-Clinical and Clinical Development

- Dermatology
- Pain
- Neurology

Clinical Partners

- SickKids Hospital
- University Health Network
- University of West Indies
- Centro de Atencion e Investigacion Medica CAIMED S.A.S.





Avicanna Quality Standard (AQS)



1

A Science First Approach

Our **world-class research** and development team is dedicated to a scientific and evidence-based approach to product development. Our strict insistence on the highest standards of scientific rigor ensures that our development processes undergo many stages of optimization, quality control and assurance. Our products undergo safety and toxicology testing throughout the development process, from the pre-clinical stage all the way to the final delivery mechanism, using both in vitro and in vivo studies.

3

Organic and Sustainable Cultivation

Our cannabis is sun-grown, natural, free of herbicides, pesticides and other harmful chemicals. We attest to organic and sustainable cultivation in accordance with **Good Agricultural and Collection Practices (GACP)** to ensure we support the health of our soils and ecosystems.

2

Solution Centric Design

Our scientists go above and beyond to collaborate with clinicians from world leading medical institutions to develop best in class **clinical development programs** with the **patient always in mind**. We design therapeutic solutions to be analyzed in pre-clinical and clinical trials and conduct observational and interventional clinical development to further study and show product safety and clinical efficacy across several therapeutic areas.

4

Safety from Start to Finish

Our products are manufactured to meet the highest standards for consistency, quality and purity every time. We use compliant **Good Manufacturing Standards (cGMP)** to assure precise delivery of cannabinoids in every product.

Executive Management Team



Aras Azadian, M.Mgmt Chief Executive Officer

Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company.

Setu Purohit, JD President and Chief Legal Officer

Setu is a lawyer and entrepreneur with experience in complex corporate and legal strategy, contract negotiations, and litigation. Setu has been involved in the cannabis industry for several years as an advocate for patients' rights and advising healthcare professionals, licensed cannabis producers, and other corporate and regulatory stakeholders in Canada and abroad. Prior to co-founding Avicanna, Setu operated his own private practice since 2012.

Dave Sohi, CPA, CA, CBV Chief Financial Officer

Dave received his Chartered Accountant designation in 2008, and following three years in audit and tax he joined the firm's business advisory practice as a manager. Dave's main focus in that group's practice was on mergers and acquisitions and valuation services. In 2010, Dave obtained his Chartered Business Valuator designation, and in 2013 joined Ernst and Young's Transaction Advisory Practice. Following a year with Ernst and Young, Dave opened his own practice where he provided clients with accounting and advisory services.

Dr. Christine Allen, PhD Chief Scientific Officer

Dr. Allen is a Full Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto. Her research is focused on the design and development of new technologies for the delivery of drugs. Dr. Allen's research has resulted in one hundred thirty peer-reviewed publications on both lipid and polymer-based drug delivery approaches. Dr. Allen has been a Professor at the University of Toronto since 2002.

UNIVERSITY OF TORONTO

Lucas Nosiglia, MFin Chief Agricultural Officer

Lucas has previous experience developing start-up companies in Argentina. In 2013, Lucas started a restaurant called La Causa Nikkei, and operated two locations in Argentina. In 2015, Lucas went on to create a marketing and event agency, Tremending, which focused on providing tailor made experiences for corporate clients. Later, in 2016, Lucas went on to provide business development consulting services for Sanatorios Guemes focused on improving the surgical and pharmaceutical practices of the major medical institution.

Arash Moghani, MBA Chief Technical Officer

Arash began his career at Deloitte as a consultant leading complex strategy and business transformation projects across several sectors globally including banking, technology and healthcare. In 2014, Arash continued his career at the Bank of Montreal, Capital Markets FX Technology department working with diverse teams of stakeholders, gathering business requirements and translating them into comprehensive technology solutions and strategies.

Janeth Mora, PharmD EVP Commercial Development

Experienced pharmaceuticals executive experienced in LATAM including her tenure at INVIMA. Janeth brings executive management experience through roles in Merck and Pfizer, where she held different positions, like Emerging Markets marketing director, as well as regulatory affairs manager in Pfizer Andean region.

Jose Beltran, MBA EVP Corporate Development

Jose offers over 30 years of pharmaceutical industry and health system executive experience across several LATAM countries with Pfizer, Abbott, Aspen and Biotoscana. Industrial engineer and marketing specialist from University of los Andes and Program for Leadership Development (PLD24) from Harvard University.

Alan Friedman Business Advisor

Alan is the founder and CEO of Rivonia Capital, a Canadian finance and capital market advisory firm. He is also a co-founder of several publicly traded companies across diversified industries. Alan is a former director of Cronos Group and oversaw the company's public listing.

Senior Scientific Team



Dr. Justin Grant, PhD, MBA

SVP Clinical Development

Dr. Grant has over 15 years experience in leading pharmaceutical research in sustained drug release formulations, has held academic positions at UHN and U of T and serves as the research program manager of the STARR Innovation Centre with Princess Margaret Cancer Centre UHN.

PRINCESS MARGARET CANCER CENTER

Dr. Amza Ali, MD, PhD, MBA

Dr. Ali is certified in Neurologist by the Federation of Royal Colleges of Physicians of the United Kingdom and launched the Epilepsy Society of the Caribbean. Additionally, he has an MBA from Rothman and an MSc in Research Methodology at the Henley Business School in the UK. Business School in the UK.

AMERICAN EPILEPSY SOCIETY

Dr. Frantz Le Devedec, PhD

SVP R&D

Frantz has over 15 years of experience in academic and industrial R&D projects, including material sciences and drug delivery formulations. He is author of over a dozen research papers and patents. His background is in biochemistry, with a PhD in applied polymer chemistry, and expertise in analytical and pharmaceutical sciences.

Samantha Watt, MSc

VP of Scientific Affairs

Samantha is an experienced scientist with years investigating human and cellular biology. With a Master's of Science from the University of Guelph, she possesses strong communication and laboratory skills that have led her to several publications and conference presentations related to plant gene manipulation and cloning.

Dr. Hance Clarke, MD, PhD

Dr. Clarke is the Director of Pain Services and the Medical Director of the Pain Research Unit at the Toronto General Hospital. He is recognized internationally for his research and novel Transitional Pain Program and researching the efficacy of cannabinoids in pain management.

TORONTO GENERAL HOSPITAL

Dr. Humberto Reynales, MD, PhD

An epidemiology with a PhD degree in science offers more than 15 years of experience in the pharmaceutical industry including his tenure at Merck & Co and his role as the executive director of Caimead a multinational CRO.

CAIMED

Dr. Mauricio Torres-Pradilla, MD, PhD

Dr. Torres-Pradilla is a dermatologist with a specialization in pediatric dermatology with research emphasis on Atopic Dermatitis, Psoriasis, Epidermolysis Bullosa and Hemangiomas. He is currently Head of Dermatology at Fundación Universitaria de Ciencias de la Salud in Bogota and Dermatologist at Debra Colombia.

FUNDACIÓN UNIVERSITARIA DE CIENCIAS

Dr. Carlos Maldonado, MD


Carlos has participated in medical and regulatory issues related to the approval and commercialization of several new medicines including Sativex in Colombia. He provides his experience in biotechnology, pharmacovigilance, clinical development through his prior roles as medical directors for companies such as Bayer.

UNIVERSIDAD NACIONAL DE COLOMBIA

Dr. Alejandro Berlin, MD, MSc

Staff Clinician-Scientist and Radiation Oncologist at the Princess Margaret Cancer Centre. His research focuses on design of innovative clinical trials, translational oncology, research expertise towards novel therapies for patients with cancer.

PRINCESS MARGARET CANCER CENTER



AVICANNA™

CONTACT

✉ info@avicanna.com

☎ (647) 243 5283

Avicanna.com